Destava

Executive Director, Cancer Vaccine Neoantigen Engineering — Early Infectious Disease

AZ is hiring for Executive Director, Cancer Vaccine Neoantigen Engineering — Early Infectious Disease in US - Cambridge Kendall SQ - MA. Executive level, $282k–$423k a year stated. First seen November 11, 2026; open as of November 13, 2026. Jobs taken straight from company career pages — no aggregator in between.

Save to applyRead more and apply on AZ's site

With Destava: How well do you fit? · Tailor my résumé · Write a cover letter

Company
AZ
Where
US - Cambridge Kendall SQ - MA
Level
Executive
Pay stated
$282k–$423k a year
First seen
November 11, 2026
Listed via
Workday

What the posting says

The role will identify, prioritize, and engineer diverse tumor antigen classes and translate them into precision multi-antigen/epitope constructs optimized for T-cell breadth, clonal expansion, functional potency, and long-term immune surveillance. The Executive Director will build deep capabilities to master the rules governing antigen processing, pMHC presentation, and TCR recognition, integrating genomic, transcriptomic, immunopeptidomic, structural, and TCR repertoire data to understand what makes an antigen naturally presented, immunologically visible, and capable of driving functional…

Read more and apply on AZ's site

This page includes information from the O*NET 31.0 Database by the U.S. Department of Labor, Employment and Training Administration (USDOL/ETA). Used under the CC BY 4.0 license. O*NET® is a trademark of USDOL/ETA.